Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Antiphospholipid Syndrome
•
Systemic lupus erythematosus
•
Benign Hematology
•
Anticoagulation
•
Hospital Medicine
How would you approach a patient with SLE and catastrophic antiphospholipid antibody system that has not responded to heparin, steroids, and PLEX?
How do you decide amongst other therapies such as eculizumab, rituximab, cyclophosphamide, IVIg?
Related Questions
How would you counsel a woman with a strong family history of thrombosis about oral contraceptives?
Do you favor obinutuzumab over voclosporin for patients with lupus nephritis and significant proteinuria and a history of non-adherence to medications?
What guides your choice between prophylactic, intermediate, and full therapeutic dosing of enoxaparin in a woman with APLS and prior fetal loss with no hx of thromboembolic disease?
Are there instances when you consider rituximab first line in a patient with class V LN?
Would you be comfortable combining rituximab with voclosporin in patients with lupus nephritis not responding to standard therapy?
What strategies have you found most effective in improving long-term medication adherence in patients with SLE?
Do you check for JCV before starting belimumab?
Would you consider using transdermal estrogen in a patient with “high risk” APLS patient on warfarin?
How would you approach rituximab dosing in a patient with SLE-Myositis overlap with LN Class III, now with worsening UPCR and concern for worsening ILD 4 months post induction and incomplete B-Cell depletion on recent labs?
How do you counsel a patient with SLE who has labs suggesting active non-renal disease on the benefits of escalation of treatment if they aren't experiencing noticeable symptoms?